RPG LIFE SCIENCES LTD.

RPG Life Sciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is effective from Wednesday, July 1, 2026, and will remain in effect until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The specific date for the board meeting to consider these results will be communicated separately. This measure is in line with SEBI regulations and the company's internal code of conduct to prevent insider trading.

RPG Life Sciences Ltd has announced Thursday, July 9, 2026, as the record date to determine eligible shareholders for a final dividend of ₹24 per equity share (300%) for the financial year ended March 31, 2026. This dividend, recommended by the Board of Directors on April 29, 2026, is subject to shareholder approval at the Nineteenth Annual General Meeting (AGM) scheduled for July 23, 2026. The AGM will be conducted via Video Conferencing (VC)/ Other Audio-Visual Means (OAVM). If approved, the dividend will be paid within 30 days of the AGM to shareholders registered as of the record date.

RPG Life Sciences Ltd has responded to a stock exchange query regarding an increase in trading volume. The company stated that all material information has been disclosed as per SEBI regulations. They clarified that there is no unpublished price-sensitive information that could explain the volume surge. RPG Life Sciences attributes the recent increase in trading volume purely to market conditions and is not aware of any specific reason for the movement.

RPG Life Sciences Ltd has issued an intimation to its shareholders holding shares in physical form, requesting them to furnish Know Your Customer (KYC) details, PAN, and Nomination information. This action is in compliance with SEBI's master circulars mandating the update of PAN, address, mobile number, bank account details, and specimen signature. Failure to update these details by April 1, 2024, may result in delayed dividend payments, which will be processed electronically only after the details are furnished. The company also encourages shareholders to dematerialize their shares for better market liquidity and provides links to relevant forms and contact information for the Registrar and Transfer Agent, MUFG Intime India Private Limited.

RPG Life Sciences has communicated to its shareholders regarding the taxation provisions for the final dividend recommended for FY 2025-26. The dividend, if approved at the AGM, will be subject to TDS (Tax Deducted at Source) as per the Income Tax Act, 2025. The tax rate will vary based on the shareholder's residential status and submitted documentation. Resident shareholders will generally face a 10% TDS, with exemptions for individuals if the dividend doesn't exceed ₹10,000. Specific forms and documentation are required for tax exemption claims by different shareholder categories. Shareholders are urged to update their PAN, residential status, and other details with their depository participants or the RTA.

RPG Life Sciences Ltd's Board of Directors, at its meeting held on April 29, 2026, approved the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026. The Board recommended a dividend of ₹24 per equity share (300% on face value of ₹8) for FY 2025-26, subject to shareholder approval. Additionally, Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for a five-year term from April 29, 2026. The Board also approved an amendment to the Code of fair disclosure and insider trading procedures. The trading window for the company's securities will open 48 hours after the results declaration.

RPG Life Sciences Ltd's Board of Directors, at its meeting on April 29, 2026, approved the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026. The Board recommended a dividend of ₹24/- (300%) per equity share of face value ₹8/- for FY 2025-26, subject to shareholder approval at the upcoming AGM. The dividend will be paid within 30 days of such approval. Additionally, Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for five years, and amendments to the Code of fair disclosure for insider trading were approved. The trading window will open 48 hours after the results declaration.

RPG Life Sciences reported strong financial results for Q4 FY26 and the full fiscal year. For Q4 FY26, revenue from operations increased by 23.6% year-on-year to ₹176.9 crores, with an EBITDA margin of 25.6%. The Domestic Formulation (DF) business grew robustly by 18.2%, outperforming the Indian Pharma Market by 1.8 times. The API division saw a significant comeback, growing 144.3% in Q4 after its unit resumed operations post-fire. For the full FY26, revenue grew 8.3% to ₹707.5 crores, maintaining a healthy EBITDA margin of 24.4%. The DF business, contributing 70% of sales, delivered 13.7% growth, driven by strong performance in key therapy baskets. The Board recommended a final dividend of ₹24 per equity share (300%) for FY26. The company plans to strengthen its product pipeline, brand equity, and global footprint.

RPG Life Sciences Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. The Board also recommended a dividend of ₹24 per equity share (300%) for FY 2025-26, subject to shareholder approval. Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for a five-year term starting April 29, 2026. Additionally, the company amended its Code of fair disclosure for insider trading.

RPG Life Sciences Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board also recommended a dividend of ₹24 per equity share (300% on a face value of ₹8) for FY 2025-26, pending shareholder approval at the upcoming Annual General Meeting. Additionally, Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for a five-year term starting April 29, 2026. The company also approved an amendment to its Code of fair disclosure and internal procedures for regulating insider trading.